# Neuland Laboratories share price today (Neuland Laboratories Ltd, NSE: NEULANDLAB)

> Neuland Laboratories share price today: ₹19,424.00 at the NSE close on 3 November 2026, up 17.9% in a year. Neuland Laboratories (NSE: NEULANDLAB) is worth ₹24,921 crore, trades at a P/E of 50.1 and has closed between ₹11,995.00 and ₹23,536.20 over the past 52 weeks. > Neuland Laboratories Ltd's earnings have grown faster than its share price. Earnings per share grew +39.9% in a year while the price moved +17.9%. NEULANDLAB · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/neuland-laboratories-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: ₹19,424.00 (+17.9% in a year)
- P/E: 50.1× (higher than 68% of the last 11 years)
- Revenue (Jun 2026): ₹642 Cr (+119.1% on a year ago)
- Profit (Jun 2026): ₹148 Cr (+957.1% on a year ago)
- Operating margin: 35.0% (+23.0 points on a year ago)
- ROCE: 26%, FY26
- ROIC: 22.6%, against a 12.0% cost of capital: +10.6 points

The main question: foreign institutions moved −4.5 percentage points over 8 quarters while the business went the other way. ## What is the Neuland Laboratories share price today? Neuland Laboratories Ltd's share price was ₹19,424.00 at the close on 3 November 2026. It has been rising for 25 weeks. That is 5.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹11,995 and ₹23,536, and at that close it sat 64% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 11 years the share price moved +3,045% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Neuland Laboratories this quarter? Two changes stood out: operating margin up 23 points on a year earlier and revenue up on a year earlier for 4 quarters in a row. 1. Operating margin up 23 points on a year earlier 35% in the June 2026 quarter, from 12%. Why: Margins rose because the company sold a different mix of products, with more higher-margin business. Next results: check if the product mix keeps margins up, since exchange-rate help may change. From the earnings call on 5 Aug 2026. 2. Revenue up on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹642 crore, +119.1% on a year earlier. Why: Revenue rose because the custom manufacturing business supplied most sales, led by its top products. Next results: check whether new projects turn into orders and whether customers keep ordering steadily. From the earnings call on 5 Aug 2026. ## What are Neuland Laboratories' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Neuland Laboratories reported revenue of ₹642 crore, up 119.1% from ₹293 crore a year earlier, and a profit of ₹148 crore, up 957.1% from ₹14.0 crore. ### Neuland Laboratories results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹642 crore | ₹293 crore | +119.1% |
| Profit | ₹148 crore | ₹14.0 crore | +957.1% |
| Earnings per share | ₹115.10 | ₹10.83 | +962.8% |
| Operating margin | 35.0% | 12.0% | +23.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Neuland Laboratories' management discussed these results on a call held on 5 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Neuland Laboratories share price history? Neuland Laboratories closed at ₹19,424.00 on 3 November 2026, up 17.9% from ₹16,473.00 a year earlier (31 October 2025) and up 1,050.3% over five years. Its highest weekly close since March 2016 was ₹23,536.20 on 11 September 2026. ### Neuland Laboratories share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹18,924.25 | +2.6% |
| 1 month ago · 1 Oct 2026 | ₹21,496.30 | −9.6% |
| 6 months ago · 30 Apr 2026 | ₹15,003.00 | +29.5% |
| 1 year ago · 31 Oct 2025 | ₹16,473.00 | +17.9% |
| 3 years ago · 3 Nov 2023 | ₹3,866.50 | +402.4% |
| 5 years ago · 4 Nov 2021 | ₹1,688.65 | +1,050.3% |
| 10 years ago · 4 Nov 2016 | ₹989.85 | +1,862.3% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹617.55 | +3,045.3% |
| Highest weekly close since March 2016, also the 52-week high · 11 Sep 2026 | ₹23,536.20 | −17.5% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹261.40 | +7,330.8% |
| 52-week low (weekly close) · 20 Mar 2026 | ₹11,995.00 | +61.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Neuland Laboratories? 3 Nov 2026: Neuland Laboratories closed at ₹19,424.00, up 2.6% on the week and down 9.6% on the month. 5 Aug 2026: Neuland Laboratories held its results call for April to June 2026. Management guided: Long-term approximately 20% growth aspiration referenced for FY27 and FY28, without adopting a specific annual guide. ### Earlier

- 24 Jul 2026: ex-date for a dividend of ₹34 a share. - Results for April to June 2026: Revenue up 119.1% and profit up 957.1% on a year earlier. ## What dividend does Neuland Laboratories pay? Neuland Laboratories paid ₹34 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.18% at the ₹19,424.00 close on 3 November 2026. The last was a dividend of ₹34 a share, ex-date 24 July 2026. ### Neuland Laboratories dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 24 Jul 2026 | ₹34 | Dividend | same day |
| 18 Jul 2025 | ₹12 | Dividend | same day |
| 12 Jul 2024 | ₹14 | Dividend | n/a |
| 11 Jul 2023 | ₹10 | Dividend | n/a |
| 14 Jul 2022 | ₹5 | Dividend | 15 Jul 2022 |
| 29 Jun 2021 | ₹3 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Neuland Laboratories Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Neuland Laboratories management say on the latest results call? On the call for April to June 2026, held on 5 August 2026, Neuland Laboratories' management guided: Long-term approximately 20% growth aspiration referenced for FY27 and FY28, without adopting a specific annual guide. > “Therefore, you may see higher EBITDA, but in terms of our plans and our long-term expectations, 25% plus is what we would be targeting, and anything above that is a bonus.”
> Saharsh Davuluri, CEO & MD, on the call for April to June 2026

### What management guided

- FY27 development revenue expected to increase; larger commercial contribution from additional molecules expected from FY28. - CMS commercialization of one additional molecule expected this year and one or two next year. - Peptide facility to be commissioned next month with manufacturing qualification; Module 1 expected fully occupied during the year and Module 2 activated if projects progress. - Forward capital spending expected much higher and qualitatively different. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/2708/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 5 August 2026.)

## What to watch in Neuland Laboratories' next results? When Neuland Laboratories reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Peptide facility commissioning and qualification - check initial-module loading and staged expansion progress in the next quarter. - What to check (from the call)
- Peptide facility commissioning and qualification - check initial-module loading and staged expansion progress in the next quarter. - CMS pipeline and order timing - check project conversion, broader molecule diversity and absence of abrupt destocking. - Margin profile - check whether mix and operating leverage continue supporting margins as exchange-rate benefits vary. ## Which stock lists is Neuland Laboratories on? Neuland Laboratories is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks. - [Momentum stocks Market cap cr: 25114.625634517764](https://www.sectoralpha.in/momentum-stocks-india)
- [Small & mid cap stocks Size rank in India: 307](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 25114.625634517764](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Neuland Laboratories profitable? Neuland Laboratories Ltd earned ₹148 Cr of net profit in the Jun 2026 quarter, +957.1% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹364 Cr. Over 10 years profit has grown 29.7% a year on average. That is 23.1% of the quarter's revenue. The same quarter a year earlier earned ₹14.0 Cr. For the full year, FY26 profit was ₹364 Cr (+40.0% on the year before). Why profit moved: revenue changed +119.1% on a year earlier and the margin moved +23.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +438.0% and revenue +82.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Neuland Laboratories make, and is it growing? Neuland Laboratories Ltd reported ₹642 Cr of revenue in the Jun 2026 quarter, +119.1% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 10 years it has grown 14.8% a year on average. The last full year, FY26, came in at ₹2,023 Cr. The last four reported quarters add to ₹2,372 Cr. FY26 revenue was ₹2,023 Cr, +37.0% on the year before. Recent pace: the last four quarters grew +82.9% on average, against 14.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +78.3%, against +20.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +181.9%, against +21.9% a year (accelerating). ## How much of every ₹100 of sales does Neuland Laboratories keep? Neuland Laboratories Ltd's operating margin was 35.0% in the Jun 2026 quarter, 23.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 9.0% and 30.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +23.0 percentage points on the year while gross margin changed +4.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Neuland Laboratories' profit turning into cash? Over the last 3 years, 100% of Neuland Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹347 Cr of operating cash against ₹364 Cr of profit. After ₹477 Cr of spending on assets, free cash was −₹130 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 100% of profit came in as cash: the cash cycle got 50 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.7× depreciation over three years. The next section checks what that spending is building. ## Where does Neuland Laboratories' cash go? Neuland Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 214 days in FY26, up from 164 days in FY21. It spent ₹807 Cr on assets over the last 3 years. Customers take 98 days to pay, and stock sits for 245 days on average. At FY26 sales of ₹2,023 Cr, each day of that cycle ties up about ₹5.5 Cr, so roughly ₹1,186 Cr is tied up in the business at any time. FY26: customers took 98 days to pay and stock sat for 245 days, about 8.1 months of sales sitting as stock, for a full cycle of 214 days, longer than FY21's 164. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 245 days. Customers pay about 98 days after that. Suppliers are paid at 129 days. Together that makes the 214-day cycle. Spending on assets: ₹807 Cr over the last 3 years, against ₹218 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹211 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Neuland Laboratories' P/E ratio, and how does it compare with its own history? Neuland Laboratories Ltd's P/E is 50.1×, in the middle of its own history: higher than 68% of past readings. Its usual P/E (the middle reading) is 36.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +39.9% while the price moved +17.9%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +63.0% a year; about +46.7% a year came from earnings growth and about +16.3 percentage points from the multiple (the market paying more); over 10 years the price moved +34.7% a year; about +28.9% a year came from earnings growth and about +5.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Neuland Laboratories business getting better or worse? Neuland Laboratories Ltd's business is turning around. Profit growth has swung from −40.2% at its low to +181.9%, improving for 3 quarters in a row, with ROCE rising at 35.3%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does Neuland Laboratories earn on its capital? Neuland Laboratories Ltd earned a ROCE of 26% in FY26. That is up from a low of 4% in FY18. Its return on capital used (ROIC) is 10.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 18.0% net margin and 0.69× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 18.0% net margin × 0.69× asset turnover × 1.56× leverage (assets divided by equity) ≈ 19.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 22.6% − 12.0% = +10.6 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 22.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 20.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Neuland Laboratories have too much debt? Neuland Laboratories Ltd has total debt of ₹301 Cr against shareholder equity of ₹1,874 Cr as of Jun 2026, so its debt is 0.16× its equity, which is very little. Year by year, that ratio went from 0.29 in FY22 to 0.16 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Neuland Laboratories shareholding pattern? Domestic institutions raised their stake in Neuland Laboratories Ltd by 9.9 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 16.3% of the company. Foreign institutions moved −4.5 points over the same period, to 21.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +9.9 points over 8 quarters, to 16.3%; Foreign institutions: −4.5 points over 8 quarters, to 21.9%; Promoters: −0.4 points over 8 quarters, to 32.3%. Why the owners changed: foreign institutions moved −4.5 points and domestic institutions +9.9 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Neuland Laboratories from balance-sheet trouble? For Neuland Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Neuland Laboratories rank in its industry? 76.0 out of 100, rank 1 of 24 in Pharma - API & CRAMS, with 96% of the evidence available. Neuland Laboratories Ltd scores 76.0 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 1. Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. The four parts add up to the total exactly: 32.3 + 22.9 + 14.1 + 6.7 = 76. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Neuland Laboratories compared with? Neuland Laboratories ranks 1 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 76.0 out of 100. 1. Neuland Laboratories Ltd this page NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Neuland Laboratories in size? Neuland Laboratories is the 8th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sai Life Sciences, Acutaas Chemicals and Piramal Pharma. Just below it: Granules India, Shilpa Medicare and OneSource Specialty Pharma. ### Pharma - API & CRAMS companies close in size

1. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) ₹33,093 crore
2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ₹32,778 crore
3. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) ₹31,807 crore
4. Neuland Laboratories Ltd ₹25,275 crore
5. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) ₹22,907 crore
6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) ₹18,690 crore
7. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ₹17,924 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Piramal Enterprises Ltd(Merged)](https://www.sectoralpha.in/stocks/piramal-enterprises-ltd-merged) ₹25,483 crore · Diversified
2. [Cholamandalam Financial Holdings Ltd](https://www.sectoralpha.in/stocks/cholamandalam-financial-holdings-ltd) ₹25,374 crore · Finance - Holding Company
3. Neuland Laboratories Ltd ₹25,275 crore
4. [Gabriel India Ltd](https://www.sectoralpha.in/stocks/gabriel-india-ltd) ₹25,255 crore · Auto Ancillaries - Shock Absorber
5. [Dalmia Bharat Ltd](https://www.sectoralpha.in/stocks/dalmia-bharat-ltd) ₹24,875 crore · Cement

## What else do people ask about Neuland Laboratories? ### What is Neuland Laboratories's share price today? Neuland Laboratories Ltd's share price is ₹19,424.00, +17.9% over the past year. The whole company is worth ₹24,921 Cr on the market. In the last 52 weeks it traded between ₹11,995 to ₹23,536; today it is 64% of the way up from the low, 5.0% above its 200-day average (as of 3 November 2026). ### What were Neuland Laboratories's latest quarterly results? Neuland Laboratories Ltd reported revenue of ₹642 Cr and net profit of ₹148 Cr for the Jun 2026 quarter. Revenue rose 119.1% and profit rose 957.1% compared with a year earlier. Earnings per share were ₹115.10. The operating margin was 35.0%, 23.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Neuland Laboratories's market cap? Neuland Laboratories Ltd's market capitalisation is ₹24,921 Cr at a share price of ₹19,424.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Neuland Laboratories performing? Neuland Laboratories Ltd's share price has been rising for 25 weeks. In its latest quarter, revenue rose 119.1% and profit rose 957.1% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Neuland Laboratories's share price go up? This page does not forecast Neuland Laboratories Ltd's share price. What it shows instead: the share price is ₹19,424.00, and it has been rising for 25 weeks. Its P/E of 50.1× is higher than 68% of its own last 11 years (as of 3 November 2026). ### Who owns Neuland Laboratories? Promoters own 32.3% of Neuland Laboratories Ltd, foreign institutions 21.9%, domestic institutions 16.3% and the public 29.6% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 9.9 percentage points over 8 quarters (as of 3 November 2026). ### Does Neuland Laboratories have too much debt? No, Neuland Laboratories Ltd has little debt: its debt is 0.16× its equity, and its operating profit is 24 times its interest bill. FY26 borrowings were ₹301 Cr against equity of ₹1,875 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Neuland Laboratories in its business cycle? Neuland Laboratories Ltd's FY26 operating margin was 29.0%, against a 13-year range of 9.0% to 30.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 35.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Neuland Laboratories story? The main question: foreign institutions moved −4.5 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Neuland Laboratories a stock worth studying right now? What the numbers show: Neuland Laboratories Ltd's earnings have grown faster than its share price. Earnings per share grew +39.9% in a year while the price moved +17.9%. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Neuland Laboratories share price forecast for 2026? What management itself guided: Long-term approximately 20% growth aspiration referenced for FY27 and FY28, without adopting a specific annual guide. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.